Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements.

Christley S, Scarborough W, Salinas E, Rounds WH, Toby IT, Fonner JM, Levin MK, Kim M, Mock SA, Jordan C, Ostmeyer J, Buntzman A, Rubelt F, Davila ML, Monson NL, Scheuermann RH, Cowell LG.

Front Immunol. 2018 May 8;9:976. doi: 10.3389/fimmu.2018.00976. eCollection 2018.

2.

VDJPipe: a pipelined tool for pre-processing immune repertoire sequencing data.

Christley S, Levin MK, Toby IT, Fonner JM, Monson NL, Rounds WH, Rubelt F, Scarborough W, Scheuermann RH, Cowell LG.

BMC Bioinformatics. 2017 Oct 11;18(1):448. doi: 10.1186/s12859-017-1853-z.

3.

Statistical classifiers for diagnosing disease from immune repertoires: a case study using multiple sclerosis.

Ostmeyer J, Christley S, Rounds WH, Toby I, Greenberg BM, Monson NL, Cowell LG.

BMC Bioinformatics. 2017 Sep 7;18(1):401. doi: 10.1186/s12859-017-1814-6.

4.

Persistence of parenchymal and perivascular T-cells in treatment-refractory anti-N-methyl-D-aspartate receptor encephalitis.

Filatenkov A, Richardson TE, Daoud E, Johnson-Welch SF, Ramirez DM, Torrealba J, Greenberg B, Monson NL, Rajaram V.

Neuroreport. 2017 Sep 27;28(14):890-895. doi: 10.1097/WNR.0000000000000851.

PMID:
28777260
5.

Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment.

Stowe AM, Ireland SJ, Ortega SB, Chen D, Huebinger RM, Tarumi T, Harris TS, Cullum CM, Rosenberg R, Monson NL, Zhang R.

J Neuroinflammation. 2017 Jul 27;14(1):149. doi: 10.1186/s12974-017-0910-x.

6.
7.

Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Rivas JR, Ireland SJ, Chkheidze R, Rounds WH, Lim J, Johnson J, Ramirez DM, Ligocki AJ, Chen D, Guzman AA, Woodhall M, Wilson PC, Meffre E, White C 3rd, Greenberg BM, Waters P, Cowell LG, Stowe AM, Monson NL.

Acta Neuropathol. 2017 Jan;133(1):43-60. doi: 10.1007/s00401-016-1627-0. Epub 2016 Oct 11.

8.

CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.

Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL.

J Immunol. 2016 Dec 1;197(11):4257-4265. Epub 2016 Oct 26.

9.

VDJML: a file format with tools for capturing the results of inferring immune receptor rearrangements.

Toby IT, Levin MK, Salinas EA, Christley S, Bhattacharya S, Breden F, Buntzman A, Corrie B, Fonner J, Gupta NT, Hershberg U, Marthandan N, Rosenfeld A, Rounds W, Rubelt F, Scarborough W, Scott JK, Uduman M, Vander Heiden JA, Scheuermann RH, Monson N, Kleinstein SH, Cowell LG.

BMC Bioinformatics. 2016 Oct 6;17(Suppl 13):333.

10.

Extended interval dosing of natalizumab in multiple sclerosis.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25.

PMID:
26917698
11.

B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.

Ireland SJ, Guzman AA, Frohman EM, Monson NL.

J Neuroimmunol. 2016 Feb 15;291:46-53. doi: 10.1016/j.jneuroim.2015.11.022. Epub 2015 Nov 26.

PMID:
26857494
12.

Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.

Chen D, Ireland SJ, Davis LS, Kong X, Stowe AM, Wang Y, White WI, Herbst R, Monson NL.

J Immunol. 2016 Feb 15;196(4):1541-9. doi: 10.4049/jimmunol.1501376. Epub 2016 Jan 13.

13.

NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component.

Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, Su L, Pratt D, Bu CH, Hildebrand S, Lyon S, Scott L, Quan J, Sun Q, Russell J, Arnett S, Jurek P, Chen D, Kravchenko VV, Mathison JC, Moresco EM, Monson NL, Ulevitch RJ, Beutler B.

Nat Immunol. 2016 Mar;17(3):250-8. doi: 10.1038/ni.3333. Epub 2015 Dec 7.

14.

Amyloid burden and sleep blood pressure in amnestic mild cognitive impairment.

Tarumi T, Harris TS, Hill C, German Z, Riley J, Turner M, Womack KB, Kerwin DR, Monson NL, Stowe AM, Mathews D, Cullum CM, Zhang R.

Neurology. 2015 Dec 1;85(22):1922-9. doi: 10.1212/WNL.0000000000002167. Epub 2015 Nov 4.

15.

A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients.

Ligocki AJ, Rivas JR, Rounds WH, Guzman AA, Li M, Spadaro M, Lahey L, Chen D, Henson PM, Graves D, Greenberg BM, Frohman EM, Ward ES, Robinson W, Meinl E, White CL 3rd, Stowe AM, Monson NL.

ASN Neuro. 2015 Oct 21;7(5). pii: 1759091415609613. doi: 10.1177/1759091415609613. Print 2015 Sep-Oct.

16.

MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing.

Rounds WH, Salinas EA, Wilks TB 2nd, Levin MK, Ligocki AJ, Ionete C, Pardo CA, Vernino S, Greenberg BM, Bigwood DW, Eastman EM, Cowell LG, Monson NL.

Gene. 2015 Nov 10;572(2):191-7. doi: 10.1016/j.gene.2015.07.011. Epub 2015 Jul 11.

17.

Stroke induces a rapid adaptive autoimmune response to novel neuronal antigens.

Ortega SB, Noorbhai I, Poinsatte K, Kong X, Anderson A, Monson NL, Stowe AM.

Discov Med. 2015 May;19(106):381-92.

18.

Antinuclear antibodies in neuromyelitis optica: guardians of the brain?

Monson N.

Eur J Neurol. 2016 Feb;23(2):223-4. doi: 10.1111/ene.12741. Epub 2015 Jun 4. No abstract available.

PMID:
26041498
19.

Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Ireland SJ, Monson NL, Davis LS.

Cytokine. 2015 Jun;73(2):236-44. doi: 10.1016/j.cyto.2015.01.009. Epub 2015 Mar 17. Review.

20.

Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

Chen D, Blazek M, Ireland S, Ortega S, Kong X, Meeuwissen A, Stowe A, Carter L, Wang Y, Herbst R, Monson NL.

J Immunol. 2014 Nov 15;193(10):4823-32. doi: 10.4049/jimmunol.1401478. Epub 2014 Oct 3.

21.

The antibody genetics of multiple sclerosis: comparing next-generation sequencing to sanger sequencing.

Rounds WH, Ligocki AJ, Levin MK, Greenberg BM, Bigwood DW, Eastman EM, Cowell LG, Monson NL.

Front Neurol. 2014 Sep 16;5:166. doi: 10.3389/fneur.2014.00166. eCollection 2014.

22.

The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

Ireland SJ, Guzman AA, O'Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL.

JAMA Neurol. 2014 Nov;71(11):1421-8. doi: 10.1001/jamaneurol.2014.1472.

23.

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.

Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO.

JAMA Neurol. 2014 May;71(5):596-602. doi: 10.1001/jamaneurol.2014.63.

PMID:
24664166
24.

Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke.

Monson NL, Ortega SB, Ireland SJ, Meeuwissen AJ, Chen D, Plautz EJ, Shubel E, Kong X, Li MK, Freriks LH, Stowe AM.

J Neuroinflammation. 2014 Jan 31;11:22. doi: 10.1186/1742-2094-11-22.

25.

Elevated CNS inflammation in patients with preclinical Alzheimer's disease.

Monson NL, Ireland SJ, Ligocki AJ, Chen D, Rounds WH, Li M, Huebinger RM, Munro Cullum C, Greenberg BM, Stowe AM, Zhang R.

J Cereb Blood Flow Metab. 2014 Jan;34(1):30-3. doi: 10.1038/jcbfm.2013.183. Epub 2013 Oct 23.

26.

Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.

Ligocki AJ, Rounds WH, Cameron EM, Harp CT, Frohman EM, Courtney AM, Vernino S, Cowell LG, Greenberg B, Monson NL.

Genes Immun. 2013 Jul-Aug;14(5):291-301. doi: 10.1038/gene.2013.18. Epub 2013 Apr 18.

27.

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC.

PLoS Pathog. 2012;8(11):e1003014. doi: 10.1371/journal.ppat.1003014. Epub 2012 Nov 8.

28.

Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.

Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM, Davis LS, Monson NL.

Autoimmunity. 2012 Aug;45(5):400-14. doi: 10.3109/08916934.2012.665529. Epub 2012 Apr 18. Review.

PMID:
22432732
29.

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.

Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E.

Mult Scler. 2012 Jul;18(7):1022-6. doi: 10.1177/1352458511432896. Epub 2012 Jan 19.

PMID:
22261118
30.

Potential impact of B cells on T cell function in multiple sclerosis.

Ireland S, Monson N.

Mult Scler Int. 2011;2011:423971. doi: 10.1155/2011/423971. Epub 2011 Mar 24.

31.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN.

PLoS One. 2011 Feb 16;6(2):e17103. doi: 10.1371/journal.pone.0017103.

32.

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL.

Eur J Immunol. 2010 Oct;40(10):2942-56. doi: 10.1002/eji.201040516.

33.

A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis.

Ligocki AJ, Lovato L, Xiang D, Guidry P, Scheuermann RH, Willis SN, Almendinger S, Racke MK, Frohman EM, Hafler DA, O'Connor KC, Monson NL.

J Neuroimmunol. 2010 Sep 14;226(1-2):192-3. doi: 10.1016/j.jneuroim.2010.06.016. Epub 2010 Jul 23.

34.

Additive effects of aboveground and belowground herbivores on the dominance of spotted knapweed (Centaurea stoebe).

Knochel DG, Monson ND, Seastedt TR.

Oecologia. 2010 Nov;164(3):701-12. doi: 10.1007/s00442-010-1708-z. Epub 2010 Jul 4.

PMID:
20607295
35.

The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, Keyserling HL, Ploss A, Rice CM, Orenstein WA, Mulligan MJ, Ahmed R.

J Immunol. 2009 Dec 15;183(12):7919-30. doi: 10.4049/jimmunol.0803903.

36.

Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Cameron EM, Spencer S, Lazarini J, Harp CT, Ward ES, Burgoon M, Owens GP, Racke MK, Bennett JL, Frohman EM, Monson NL.

J Neuroimmunol. 2009 Aug 18;213(1-2):123-30. doi: 10.1016/j.jneuroim.2009.05.014. Epub 2009 Jul 24.

37.

Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis.

Stüve O, Korth C, Gabatto P, Cameron EM, Hu W, Eagar TN, Monson NL, Frohman EM, Racke MK, Zabetian CP, Oksenberg JR.

Arch Neurol. 2009 Feb;66(2):280-1. doi: 10.1001/archneur.66.2.280. No abstract available.

PMID:
19204171
38.

Immunologic mechanisms of multiple sclerosis.

Frohman EM, Eagar T, Monson N, Stuve O, Karandikar N.

Neuroimaging Clin N Am. 2008 Nov;18(4):577-88, ix. doi: 10.1016/j.nic.2008.06.009. Review.

PMID:
19068403
39.

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK.

Neurology. 2009 Feb 3;72(5):396-401. doi: 10.1212/01.wnl.0000327341.89587.76. Epub 2008 Nov 5.

40.

Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis.

Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL.

Clin Immunol. 2008 Sep;128(3):382-91. doi: 10.1016/j.clim.2008.05.002. Epub 2008 Jul 2.

PMID:
18599355
41.

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Zhu H, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P Jr, Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, del Rio C, Altman J, Ahmed R.

J Infect Dis. 2008 Aug 15;198(4):500-7. doi: 10.1086/590187.

42.

The natural history of B cells.

Monson NL.

Curr Opin Neurol. 2008 Apr;21 Suppl 1:S3-8. doi: 10.1097/01.wco.0000313358.53553.c7. Review.

PMID:
18388800
43.

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.

Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, Stuve O, Monson N, Racke MK, Jacobson S.

PLoS One. 2008 Apr 30;3(4):e2028. doi: 10.1371/journal.pone.0002028.

44.

High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes.

Stüve O, Cravens PD, Singh MP, Frohman EM, Phillips JT, Remington G, Hu W, Hemmer B, Olek MJ, Monson NL, Racke MK.

Arch Neurol. 2007 Jul;64(7):1055-6. No abstract available.

PMID:
17620501
45.

Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS.

Lambracht-Washington D, O'Connor KC, Cameron EM, Jowdry A, Ward ES, Frohman E, Racke MK, Monson NL.

J Neuroimmunol. 2007 May;186(1-2):164-76. Epub 2007 Apr 23.

46.

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.

Arch Neurol. 2007 Feb;64(2):169-76. Review.

PMID:
17296831
47.

Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection.

Harp C, Lee J, Lambracht-Washington D, Cameron E, Olsen G, Frohman E, Racke M, Monson N.

J Neuroimmunol. 2007 Feb;183(1-2):189-99. Epub 2006 Dec 13.

48.
49.

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.

Arch Neurol. 2006 Oct;63(10):1383-7.

PMID:
17030653
50.

Immune surveillance in multiple sclerosis patients treated with natalizumab.

Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK.

Ann Neurol. 2006 May;59(5):743-7.

PMID:
16634029

Supplemental Content

Loading ...
Support Center